EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Rational design of novel macrocyclic peptide PET tracers targeting urokinase-type plasminogen activator receptor

Suyun Pu, Jiale Xie, Chuan Chen, Wenhao Liu, Jie Wang, Weiyan Li, Kezhi Ding, Yabin Yang, Jiawen Huang, Ding Lin, Jian Gao, Zonghua Luo

Acta Pharmaceutica Sinica B · 2026-11

DOI: 10.1016/j.apsb.2026.11.001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2026-11. Verfasst von Suyun Pu und 11 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ShanghaiTech University, Shanghai University of Medicine and Health Sciences Shanghai Key Laboratory of Molecular Imaging.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The overexpression of urokinase-type plasminogen activator receptor (uPAR) is a key marker in tumor aggressiveness and metastasis. However, the development of uPAR-targeted positron emission tomography (PET) tracers is hindered by the poor metabolic stability and rapid clearance of linear peptide probes. To address this, we designed a novel class of macrocyclic peptide tracers via integrated sequence optimization and head-to-tail macrocyclization, followed by systematic 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-spacer modification for pharmacokinetic tuning. Radiolabeling with gallium-68 yielded high-affinity probes, from which the polysarcosine-linked tracer [ 68 Ga]Ga-P8 was selected as the lead candidate. In uPAR-expressing xenograft models, [ 68 Ga]Ga-P8 exhibited significantly improved imaging performance over the clinical reference [ 68 Ga]Ga-DOTA-AE105 , with an 8.7-fold increase in tumor retention, rapid blood clearance, and superior tumor-to-background contrast. Its target specificity was validated by in vivo blocking and ex vivo correlative autoradiography and immunohistochemistry. This work not only presents [ 68 Ga]Ga-P8 as a next-generation uPAR imaging agent but also establishes a generalizable design framework for stable, high-contrast peptide radiopharmaceuticals.

Förderung

  • ShanghaiTech University
  • Shanghai University of Medicine and Health Sciences Shanghai Key Laboratory of Molecular Imaging

Zitieren

APA

Pu, S., Xie, J., Chen, C., Liu, W., Wang, J., Li, W., Ding, K., Yang, Y., Huang, J., Lin, D., Gao, J., & Luo, Z. (2026). Rational design of novel macrocyclic peptide PET tracers targeting urokinase-type plasminogen activator receptor. Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2026.11.001

Vancouver

Pu S, Xie J, Chen C, Liu W, Wang J, Li W, et al. Rational design of novel macrocyclic peptide PET tracers targeting urokinase-type plasminogen activator receptor. Acta Pharmaceutica Sinica B. 2026. doi:10.1016/j.apsb.2026.11.001

BibTeX
@article{Pu2026,
  author = {Pu, Suyun and Xie, Jiale and Chen, Chuan and Liu, Wenhao and Wang, Jie and Li, Weiyan and Ding, Kezhi and Yang, Yabin and Huang, Jiawen and Lin, Ding and Gao, Jian and Luo, Zonghua},
  title = {Rational design of novel macrocyclic peptide PET tracers targeting urokinase-type plasminogen activator receptor},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2026},
  doi = {10.1016/j.apsb.2026.11.001}
}
Kostenlos starten →